Slowing the progression of Alzheimer's disease; what works?

Ageing Research Reviews

Volumn 23, Issue , 2015, Pages 193-209

  Nelson, Lucy ^a   Tabet, Naji ^b  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Alzheimer's disease; Blood pressure; Cognition; Diet; Exercise

Indexed keywords

5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; CHOLINESTERASE INHIBITOR; CURCUMIN; CYANOCOBALAMIN; FOLIC ACID; GINKGO BILOBA EXTRACT; MULTIVITAMIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OMEGA 3 FATTY ACID; PYRIDOXINE; RESVERATROL; SOLANEZUMAB; VITAMIN D;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC DISEASE; COGNITION; CONTROLLED CLINICAL TRIAL (TOPIC); DEMENTIA; DIET; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE SEVERITY; EXERCISE; HUMAN; HYPOTENSION; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOCIAL NETWORK; VITAMIN SUPPLEMENTATION; ANIMAL; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE PROGRESSION; HUMANS;

EID: 84941170373     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2015.07.002     Document Type: Review

References (271)

1. Abou A., et al. Swimming as a positive moderator of cognitive aging: a cross-sectional study with a multitask approach. J. Aging Res. 2012, 273185. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3541603&tool=pmcentrez&rendertype=abstract (accessed 06.26.15.).
2. Afzal S., Bojesen S.E., Nordestgaard B.G. Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia. Alzheimer's Dementia J. Alzheimer's Assoc. 2014, 10(3):296-302. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23871764 (Accessed 05.18. 15.].
3. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009, 41:40-59. Available at http://www.ncbi.nlm.nih.gov/pubmed/18662800.
4. Aisen P.S., et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008, 300(15):1774-1783. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2684821&tool=pmcentrez&rendertype=abstract (accessed 02.16.15.).
5. Aizenstein H.J., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008, 65:1509-1517. Available at http://www.ncbi.nlm.nih.gov/pubmed/19001171.
6. Albinet C.T., et al. Increased heart rate variability and executive performance after aerobic training in the elderly. Eur. J. Appl. Physiol. 2010, 109(4):617-624. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20186426 (accessed 01.08.15).
7. Annweiler C., et al. Higher vitamin D dietary intake is associated with lower risk of alzheimer's disease: a 7-year follow-up. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 2012, 67(11):1205-1211. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22503994(accessed 04.13.15.).
8. Annweiler C., Beauchet O. Questioning vitamin D status of elderly fallers and nonfallers: a meta-analysis to address a forgotten step. J. Int. Med. 2015, 277(1):16-44. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24697944 (accessed 03.09.15.).
9. APA, 2014. DSM-5. American Psychiatric Association. Available at: (accessed 05.26.15.). http://www.dsm5.org/Pages/Default.aspx.
10. Appleby B.S., et al. A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement. Geriatr. Cogn. Disord. 2013, 35:1-2. Available at:http://www.ncbi.nlm.nih.gov/pubmed/23307039.
11. Arkema E.V., et al. Exposure to ultraviolet-B and risk of developing rheumatoid arthritis among women in the nurses' health study. Annal. Rheumatic Dis. 2013, 72(4):506-511. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3678095&tool=pmcentrez&rendertype=abstract (accessed 05.05.15.).
12. Arkin S. Language-enriched exercise plus socialization slows cognitive decline in Alzheimer's disease. Am. J. Alzheimer's Dis. Other Dementias 2007, 22(1):62-77. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17534004 (accessed 02.26.15.).
13. Articus K., et al. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int. J. Clin. Pract. 2011, (7):790-796. Available at: http://www.ncbi.nlm.nih.gov/pubmed/215184 (accessed 02.25. .15).
14. Atella V., Kopinska J. Body weight, eating patterns, and physical activity: the role of education. Demography 2014, 51(4):1225-1249. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20384 (accessed 01.13.15.).
15. Atri A., et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2015, 22(3):209-221. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2718545&tool=pmcentrez&rendertype=abstract (accessed 02.16.15.).
16. Auld D.S., et al. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 2002, 68:209-245. Availabe at: http://www.ncbi.nlm.nih.gov/pubmed/12450488.
17. Bahar-Fuchs A., Clare L., Woods B. Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer's or vascular type: a review. Alzheimer's Res. Ther. 2013, 5(4):35. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3979126&tool=pmcentrez&rendertype=abstract (accessed 02.09.15.).
18. Ballard C., et al. Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. PLoS One 2012, 7(6):e37410. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3376123&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
19. Ballard C., Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst. Rev. 2006, p.CD003476. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16437455 (accessed 12.16. .14.).
20. Balouch S., Rusted J.M. Error-monitoring in an everyday task in people with Alzheimer-type dementia: observations over five years of performance decline. J. Clin. Exp. Neuropsychol. 2014, 36(7):773-786. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25116037 (accessed 02.13.15.).
21. Banach M., Aronow W.S. Blood pressure j-curve: current concepts. Curr. Hypertens. Rep. 2012, 14(6):556-566. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3490060&tool=pmcentrez&rendertype=abstract(accessed 06.16.15.).
22. Banerjee S., et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial-a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol. Assess. (Winchester, England) 2013, 17(7):1-166. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23438937 (accessed 02.26.15).
23. Baum L., et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 2008, 28:110-113. Available at http://www.ncbi.nlm.nih.gov/pubmed/18204357.
24. Beason-Held L.L., et al. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke 2007, 38:1766-1773. Available at http://www.ncbi.nlm.nih.gov/pubmed/17510458.
25. Belkacemi A., Ramassamy C. Time sequence of oxidative stress in the brain from transgenic mouse models of Alzheimer's disease related to the amyloid-β cascade. Free Radic. Biol. Med. 2012, 52(3):593-600. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22172527 (accessed 02.26.15).
26. Berg L., et al. Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann. Neurol. 1988, 23:477-484. Available at http://www.ncbi.nlm.nih.gov/pubmed/3389756.
27. Bernier F., et al. Clinical study of E260, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimer's Dementia 2013, 9(4):P886. Available at: http://www.alzheimersanddementia.com/article/S155252601302760X/fulltext (accessed 06.19.15.).
28. Bherer L., Erickson K.I., Liu-Ambrose T. Physical exercise and brain functions in older adults. J. Aging Res. 2013, 197326. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3791662&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
29. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 2006, CD005593:CD005593. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16437532 (accessed 10. 27.14.).
30. Birks J., Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2009, 1:CD003120. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19160216 (accessed 02.26.15.).
31. Bjelakovic G., Nikolova D., Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm. PLoS One 2013, 8(9):e74558. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3765487&tool=pmcentrez&rendertype=abstract (accessed 02. 26.15.).
32. Bredesen D.E. Reversal of cognitive decline: a novel therapeutic program. Aging 2014, 6(9):707-717. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4221920&tool=pmcentrez&rendertype=abstract (accessed 02.23.15.).
33. Breitner J.C., et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011, 7:402-411. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21784351.
34. Burns A., Jacoby R., Levy R. Progression of cognitive impairment in Alzheimer's disease. J. Am. Geriatr. Soc. 1991, 39:39-45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1987255.
35. Burton D.A., Nicholson G., Hall G.M. Anaesthesia in elderly patients with neurodegenerative disorders: special considerations. Drugs Aging 2004, 21(4):229-242. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15012169 (accessed 02.25.15.).
36. Cai W., et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(13):4940-4945. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=39772&tool=pmcentrez&rendertype=abstract (accessed 05.10.15.).
37. Canevelli M., et al. Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study. Phytomed. Int. J. Phytother. Phytopharmacol. 2014, 21(6):888-892. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24548724 (accessed 02.26.15.).
38. Chui H.C., et al. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch. Neurol. 1994, 51(7):676-681. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8018040 (accessed 02.25.15.).
39. Clare L., et al. Awareness in early-stage Alzheimer's disease: relationship to outcome of cognitive rehabilitation. J. Clin. Exp. Neuropsychol. 2004, 26(2):215-226. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15202541 (accessed 02. 26.15.).
40. Clare L., et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry 2010, 18(10):928-939. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20808145 (accessed 02.25.15.).
41. Cohen-Mansfield J., et al. The value of social attributes of stimuli for promoting engagement in persons with dementia. J. Nerv. Mental Dis. 2010, 198(8):586-592. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3132&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
42. Cohen-Mansfield J., Werner P. Management of verbally disruptive behaviors in nursing home residents. J. Gerontol. Ser. A. Biol. Sci. Med. Sci. 1997, 26(2015):M369-M377. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9402944 (accessed 02.26.15.).
43. Cooper J.K., Mungas D., Weiler P.G. Relation of cognitive status and abnormal behaviors in Alzheimer's disease. J. Am. Geriatr. Soc. 1990, 38(8):867-870. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2201714 (Accessed 02.25.15.).
44. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8346443.
45. Cummings J.L., Morstorf T., Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Res. Ther. 2014, 6(4):37. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4095696&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
46. Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia 2013, 61:71-90. Available at http://www.ncbi.nlm.nih.gov/pubmed/22674585.
47. Danysz W., Parsons C.G. Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine-searching for the connections. Br. J. Pharmacol. 2012, 167:324-352. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22646481.
48. DeMattos R.B., et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(15):8850-8855. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=37524&tool=pmcentrez&rendertype=abstract (accessed 05.27.15.).
49. Devore E.E., et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am. J. Clin. Nutr. 2009, 90(1):170-176. Available at:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=299&tool=pmcentrez&rendertype=abstract (accessed 02. 02.15.).
50. Doody R.S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. New Engl. J. Med. 2014, 370(4):311-321. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24450890 (accessed 02.06.15.).
51. Drachman D.A., et al. The prognosis in Alzheimer's disease. How far rather than how fast best predicts the course. Arch Neurol. 1990, 47:851-856. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2375690.
52. Dumont C., et al. Predictive factors for rapid loss on the mini-mental state examination in Alzheimer's disease. J. Nutr. Health Aging 2005, 9(3):163-167. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15864396 (accessed 02.26.15.).
53. Dysken M.W., et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014, 311(1):33-44. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4109898&tool=pmcentrez&rendertype=abstract (accessed 11.06.14.).
54. Eckert G.P., et al. Mitochondrial dysfunction-a pharmacological target in Alzheimer's disease. Mol. Neurobiol. 2012, 46(1):136-150. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22552779 (accessed 02.26.15.).
55. Edahiro A., et al. Factors affecting independence in eating among elderly with Alzheimer's disease. Geriatrics Gerontol. Int. 2012, 12(3):481-490. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22233202 (accessed 02.26.15.).
56. Emanuel J.E., et al. Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am. J. Geriatric Psychiatry: Off. J. Am. Assoc. Geriatric Psychiatry 2011, 19(2):160-168. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=30005&tool=pmcentrezrendertype=abstract (accessed 02.26.15.).
57. Engelborghs S., et al. Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. Int. J. Geriatr. Psychiatry 2004, 19(4):365-370. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15065230 (accessed 02.26.15.).
58. Engelhart M.J., et al. Inflammatory proteins in plasma and the risk of dementithe: rotterdam study. Arch. Neurol. 2004, 61:668-672. Available at http://www.ncbi.nlm.nih.gov/pubmed/15148142.
59. Evans S., et al. Cognitive and neural signatures of the APOE E4 allele in mid-aged adults. Neurobiol. Aging 2014, 357:1615-1623. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4001126&tool=pmcentrez&rendertype=abstract (accessed 01.19.15.).
60. Even C., Weintraub D. Case for and against specificity of depression in Alzheimer's disease. Psychiatry Clin. Neurosci. 2010, 64(4):358-366. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20573052 (accessed 02.26.15.).
61. Evered L., et al. Postoperative cognitive dysfunction is independent of type of surgery and anesthetic. Anesth. Analg. 2011, 112(5):1179-1185. Available at:http://www.ncbi.nlm.nih.gov/pubmed/21474666 (accessed 02.25.15.).
62. Farina N., et al. Cochrane Database of Systematic Reviews 2012, John Wiley & Sons, Ltd., Chichester, UK, Available at: http://www.ncbi.nlm.nih.gov/pubmed/23152215 (accessed 02.17.15.).
63. Farina N., Rusted J., Tabet N. The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review. Int. Psychogeriatrics 2014, 26(1):9-18. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23962667 (accessed 02.16.15.).
64. Ferris L.T., Williams J.S., Shen C.-L. The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. Med. Sci. Sports Exerc. 2007, 39(4):728-734. Available at:http://www.ncbi.nlm.nih.gov/pubmed/17414812 (accessed 01. 23.15.).
65. Fick D.M., et al. Delirium in early-stage alzheimer's disease: enhancing cognitive reserve as a possible preventive measure. J. Gerontol. Nursing 2009, 35(3):30-38. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2814421&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
66. Fick D.M., Agostini J.V., Inouye S.K. Delirium superimposed on dementia: a systematic review. J. Am. Geriatr. Soc. 2002, 50(10):1723-1732. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12366629 (accessed 02.25.15.).
67. Fong T.G., et al. Delirium accelerates cognitive decline in Alzheimer disease. Neurology 2009, 72(18):1570-1575. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2677tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
68. Ford A.H., Almeida O.P. Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. J. Alzheimer's Dis.: JAD 2012, 29(1):133-149. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22232016 (accessed 02.26.15.).
69. Forman M., et al. The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease. Alzheimer's Dementia 2013, 9(4):P139. Available at: http://www.alzheimersanddementia.com/article/S1552526013002343/fulltext (accessed 06.19.15.).
70. Fournier A., et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev. Neurother. 2009, 9(9):1413-1431. Available at:http://www.ncbi.nlm.nih.gov/pubmed/19769454 (accessed 02.25.15.).
71. Fratiglioni L., et al. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet 2000, 355(9212):1315-1319. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10776744 (accessed 01.23.15.).
72. Frautschy S.A., Cole G.M. Why pleiotropic interventions are needed for Alzheimer's disease. Mol. Neurobiol. 2010, 41(2-3):392-409. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2876259&tool=pmcentrez&rendertype=abstract (accessed 06.12.15.).
73. Freund-Levi Y., et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 2006, 63(10):1402-1408. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17030655 (accessed 02.26.15.).
74. Frisardi V., et al. Nutraceutical properties of Mediterranean diet and cognitive decline: possible underlying mechanisms. J. Alzheimer's Dis.: JAD 2010, 22(3):715-740. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20858954 (accessed 02.26.15.).
75. Frisardi V., Imbimbo B.P. Metabolic-cognitive syndrome: metabolic approach for the management of Alzheimer's disease risk. J. Alzheimers Dis. 2012, 30(Suppl 2):S1-S4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22596269.
76. Gard P.R., et al. Blockade of pro-cognitive effects of angiotensin IV and physostigmine in mice by oxytocin antagonism. Eur. J. Pharmacol. 2012, 683:155-160. Available at http://www.ncbi.nlm.nih.gov/pubmed/22433837.
77. Gard P.R., Rusted J.M. Angiotensin and Alzheimer's disease: therapeutic prospects. Expert Rev. Neurother. 2004, 4:87-96. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15853619.
78. Gasior M., Rogawski M.A., Hartman A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol. 2006, 17(5-6):431-439. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2367001&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
79. Giannakopoulos P., et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500. Available at http://www.ncbi.nlm.nih.gov/pubmed/12743238.
80. Gillette-Guyonnet S., et al. Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimer's & dementia. J. Alzheimer's Assoc. 2011, 7(6):579-592. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22055975 (accessed 02.25.15.).
81. Grant W.B. Trends in diet and Alzheimer's disease during the nutrition transition in Japan and developing countries. J. Alzheimer's Dis.: JAD 2014, 38(3):611-620. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24037034 (accessed 02.24.15.).
82. Green R.C., et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch. Neurol. 2003, 60(5):753-759. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12756140 (accessed 02.26.15.).
83. Grimm M.O.W., et al. Impact of Vitamin D on amyloid precursor protein processing and amyloid-β peptide degradation in Alzheimer's disease. Neuro-Degenerative Dis. 2014, 13(2-3):75-81. Available at: http://www.karger.com/Article/FullText/355462 (accessed 05.20. .15.).
84. Gu Y., et al. Food combination and Alzheimer disease risk: a protective diet. Arch. Neurol. 2010, 67(6):699-706. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3029147&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
85. Guo Z., et al. Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. J. Am. Geriatr. Soc. 1999, 47:723-726. Available at http://www.ncbi.nlm.nih.gov/pubmed/10366174.
86. Gustafsson P.E., Persson M., Hammarström A. Socio-economic disadvantage and body mass over the life course in women and men: results from the Northern Swedish Cohort. Eur. J. Public Health 2012, 22(3):322-327. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21616991 (accessed 02.26.15.).
87. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12130773.
88. Harrison N.A., et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 2009, 66:407-414. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19423079.
89. Hassing L.B., et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 2004, 33:355-361. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15136287.
90. Henderson S.T., Poirier J. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study. BMC Med. Genet. 2011, 12:137. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3213220&tool=pmcentrez&rendertype=abstract (accessed 02.06.15.).
91. Henry G., Williamson D., Tampi R.R. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am. J. Alzheimers Dis. Other Demen 2011, 26:169-183. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21429956.
92. Hoffman L.B., et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 2009, 72(20):1720-1726. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2373tool=pmcentrez&rendertype=abstract (accessed 02.25.15.).
93. Holmes C., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18640458.
94. Holmes C., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73:768-774. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19738171.
95. Horner J., et al. Swallowing in Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 1994, 8(3):177-189. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7986487 (accessed 02.26.15.).
96. Huff F.J., et al. Age at onset and rate of progression of Alzheimer's disease. J. Am. Geriatr. Soc. 1987, 35:27-30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3794143.
97. Humbert I.A., et al. Early deficits in cortical control of swallowing in Alzheimer's disease. J. Alzheimer's Dis.: JAD 2010, 19(4):1185-1197. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2891325&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
98. Ihl R., Tribanek M., Bachinskaya N. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry 2012, 45(2):41-46. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22086747 (accessed 02.26.15.).
99. Jacobs D., et al. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994, 44:1215-1220. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8035918.
100. James P.A., et al. 2014. evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA: J. Am. Med. Assoc. 2014, 311(5):507-520. Available at: http://jama.network.com/article.aspx?articleid=1791497 (accessed 07.09.14.).
101. Jaturapatporn D., et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev. 2012, CD006378. Available at http://www.ncbi.nlm.nih.gov/pubmed/22336816.
102. Jones R.N., et al. Does educational attainment contribute to risk for delirium? A potential role for cognitive reserve. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 2006, 61(12):1307-1311. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17234825 (accessed 02.26.15.).
103. Keleshian V.L., et al. Aging is associated with altered inflammatory, arachidonic acid cascade, and synaptic markers, influenced by epigenetic modifications, in the human frontal cortex. J. Neurochem. 2013, 125:63-73. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23336521.
104. Kim G., et al. Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey. J. Alzheimer's Dis.: JAD 2013, 33(3):853-862. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23042212 (accessed 02.26.15.).
105. Kim H., Lee K.J. Serum homocysteine levels are correlated with behavioral and psychological symptoms of Alzheimer's disease. Neuropsychiatr. Dis. Treatment 2014, 10:1887-1896. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4200070&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
106. Kimura M., et al. Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. Brain Res. 2005, 1047:72-84. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15893738.
107. Kirk-Sanchez N.J., McGough E.L. Physical exercise and cognitive performance in the elderly: current perspectives. Clin. Interv. Aging 2014, 9:51-62. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3872007&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
108. Kivipelto M., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001, 322:1447-1451. Available at http://www.ncbi.nlm.nih.gov/pubmed/11408299.
109. Klinkenberg I., Sambeth A., Blokland A. Acetylcholine and attention. Behav. Brain Res. 2011, 221:430-442. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21108972.
110. Klugman A., et al. Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors. J. Alzheimers Dis. 2012, 30:467-474. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22451323.
111. Kohut M.L., et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav. Immun. 2006, 20(3):201-209. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16504463 (accessed 02.26.15.).
112. Kokmen E., et al. Clinical risk factors for Alzheimer's disease: a population-based case-control study. Neurology 1991, 41:1393-1397. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1891088.
113. Koppel J., et al. Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities. Neurobiol. Aging 2014, 35(9):2021-2028. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24731519 (accessed 02.26.15.).
114. Koppel J., et al. Relationships between behavioral syndromes and cognitive domains in Alzheimer disease: the impact of mood and psychosis. Am. J. Geriatr. Psychiatry: Off. J. Am. Assoc. Geriatric Psychiatry 2012, 20(11):994-1000. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22048323 (accessed 02.26.15.).
115. Krstic D., Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 2012, 9:25-34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23183882.
116. Kuehn B.M. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005, 293(20):2462. Available at: http://jama.network.com/article.aspx?articleid=200951 (accessed 02.28.15.).
117. De la Fuente M. Effects of antioxidants on immune system ageing. Eur. J. Clin. Nutr. 2002, 56(Suppl 3):S5-S8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12142953 (accessed 02.26.15.).
118. De la Torre J.C. How do become risk factors for Alzheimer's disease?. Neurol. Res. 2006, 28:637-644. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16945216.
119. De la Torre J.C. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc. Psychiatry Neurol. 2012, 367516. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23243502.
120. Lai R., et al. First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing. Alzheimer's Dementia 2012, 8(4):P96. Available at: http://www.alzheimersanddementia.com/article/S155252601200369X/fulltext (accessed 04.26.15.).
121. Lattanzi S., et al. Blood pressure variability predicts cognitive decline in Alzheimer's disease patients. Neurobiol. Aging 2014, 35(10):2282-2287. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24856056 (accessed 01.11.15.).
122. Lee H.B., Lyketsos C.G. Depression in Alzheimer's disease: heterogeneity and related issues. Biol. Psychiatry 2003, 54(3):353-362. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12893110 (accessed 02.26.15.).
123. Leung R., et al. Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One 2013, 4971. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3677891&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
124. Liao D., et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke 1996, 27:2262-2270. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8969791.
125. Littlejohns T.J., et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology 2014, 83(10):920-928. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4153851&tool=pmcentrez&rendertype=abstract (accessed 04.02.15.).
126. Liu H., et al. Optimal blood pressure for cognitive function: findings from an elderly African-American cohort study. J. Am. Geriatr. Soc. 2013, 61(6):875-881. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3686917&tool=pmcentrez&rendertype=abstract (accessed 02.25.15.).
127. Lloret A., et al. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimer's Dis.:JAD 2009, 17(1):143-149. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19494439 [accessed 02.1.15.).
128. Logsdon R.G., McCurry S.M., Teri L. Evidence-based interventions to improve quality of life for individuals with dementia. Alzheimer's Care Today 2007, 8(4):309-318. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2585781&tool=pmcentrez&rendertype=abstract (accessed 02.19.15.).
129. Lopez O.L., et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 2009, 80(6):600-607. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=28235&tool=pmcentrez&rendertype=abstract (accessed 02.06.15.).
130. Lopez O.L., et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am. J. Psychiatry 2013, 170(9):1051-1058. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3990263&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
131. Lu C., et al. Design, synthesis, and evaluation of resveratrol derivatives as As(1-[U+2084]S) aggregation inhibitors, antioxidants, and neuroprotective agents. Bioorg. Med. Chem. Lett. 2012, 22:7683-7687. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23127891.
132. Lucca U., et al. Rate of progression and prognostic factors in Alzheimer's disease: a prospective study. J. Am. Geriatr. Soc. 1993, 41:45-49. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8418122.
133. Luchsinger J.A. Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention?. J. Alzheimer's Dis.: JAD 2010, 20(3):723-736. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20413862 (accessed 02.26.15.).
134. Maes M., et al. Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease. J. Psychiatr Res. 1999, 33:397-405. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10504008.
135. Maezawa I., et al. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J. Biol. Chem. 2011, 286(5):3693-3706. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3030372&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
136. Mandal P.K., et al. NMR investigations of amyloid-β peptide interactions with propofol at clinically relevant concentrations with and without aqueous halothane solution. J. Alzheimer's Dis. JAD 2010, 21(4):1303-1309. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21504123 (accessed 02.26.15.).
137. Mandal P.K., Fodale V. Isoflurane and desflurane at clinically relevant concentrations induce amyloid beta-peptide oligomerization: an NMR study. Biochem. Biophys. Res. Commun. 2009, 379(3):716-720. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19116131 (accessed 02. 26.15.).
138. Mazza M., et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur. J. Neurol.: Off. J. Eur. Fed. Neurol. Soc. 2006, 13(9):981-985. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16930364 (accessed 02.26.15.).
139. McCleary R., et al. Full-information models for multiple psychometric tests: annualized rates of change in normal aging and dementia. Alzheimer Dis. Assoc. Disord. 1996, 10:216-223. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8939281.
140. McGohan L.D. Clinical updates: delirium. J. Contin. Educ. Nurs. 2005, (3):102-103. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16022028 (accessed 02.06.15.).
141. McKhann G.M., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21514250.
142. Mehrabian S., et al. Relationship between orthostatic hypotension and cognitive impairment in the elderly. J. Neurol. Sci. 2010, 299(1-2):45-48. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2050 (accessed 02.23.15.).
143. Miranda-Castillo C., et al. Unmet needs, quality of life and support networks of people with dementia living at home. Health Qual. Life Outcomes 2010, 8:132. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2995780&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
144. Misiak B., Leszek J., Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer's disease-the emerging role of systemic low-grade inflammation and adiposity. Brain Res. Bull. 2012, 89:144-149. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22921944.
145. Moon J.H., et al. Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). Clin. Endocrinol. 2015, Available at: http://www.ncbi.nlm.nih.gov/pubmed/25641087 (accessed 05.08.15.).
146. Morales I., et al. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front. Cell Neurosci. 2014, 112. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24795567.
147. Morris J.C., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993, 43:2457-2465. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8255439.
148. Mortimer J.A., et al. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992, 42:1689-1696. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1513455.
149. Navarro-Gil P., et al. Which factors are associated with mortality in institutionalized older adults with dementia. Arch. Gerontol. Geriatr. 2014, 59(3):522-527. Available at: http://www.sciencedirect.com/science/article/pii/S01694314001101 (accessed 03.02.15.).
150. Nelson L., Gard P., Tabet N. Hypertension and inflammation in Alzheimer's disease: close partners in disease development and progression!. J. Alzheimers Dis. 2014, 41:331-343. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24614908.
151. NHS, 2014. High Blood Pressure (Hypertension). NHS Choices. Available at:(accessed 02.28.15.). http://www.nhs.uk/conditions/blood-pressure-(high)/pages/introduction.aspx.
152. NICE, 2006. Dementia: Supporting people with dementia and their carers in health and social care. NICE guidelines [CG42]. Available at: (accessed 02.28.15.). http://www.nice.org.uk/guidance/cg42.
153. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15831717.
154. Norden D.M., Godbout J.P. Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol. Appl. Neurobiol. 2013, 39:19-34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23039106.
155. O'Hara R., et al. Which Alzheimer patients are at risk for rapid cognitive decline. J. Geriatr. Psychiatry Neurol. 2002, 15:233-238. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12489920.
156. Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am. J. Hypertens. 2000, 13(5 Pt 1):461-467. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10826395 (accessed 16.06.15).
157. Ogihara T., et al. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens. Res. Off. J. Japan. Soc. Hypertens. 2008, 31(8):1595-1601. Available at: http://dx.doi.org/10.1291/hypres.31.1595 (accessed 06.16.15.).
158. Ohrui T., et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004, 63:1324-1325. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15477567.
159. Olin J.T., et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatric Psychiatry 2002, 10(2):125-128. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11925273 (accessed 02.26.15.).
160. Orrell M., et al. Maintenance cognitive stimulation therapy for dementia: single-blind, multicentre, pragmatic randomised controlled trial. Br. J. Psychiatry: J. Mental Sci. 2014, 204(6):454-461. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24676963 (accessed 02.6.15.).
161. Overall J.E., et al. Empirical scaling of the stages of cognitive decline in senile dementia. J. Geriatr. Psychiatry Neurol. 1990, 3:212-220. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2073309.
162. Panza F., et al. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev. Clin. Immunol. 2014, 10(3):405-419. Available at: http://informahealthcare.com/doi/abs/10.1586/1744666X 2014.883921 (accessed 06.30.15.).
163. Paris J.J., et al. Central administration of angiotensin IV rapidly enhances novel object recognition among mice. Neuropharmacology 2013, 70:247-253. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23416700.
164. Paulsen J.S., et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000, 54(10):1965-1971. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10822438 (accessed 02.26.15.).
165. Perrone L., Grant W.B. Observational and ecological studies of dietary advanced glycation end products in national diets and Alzheimer's disease incidence and prevalence. J. Alzheimer's Dis.: JAD 2015, 45(3):965-979. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25633677 (accessed 05.20.15.).
166. Petitti D.B., et al. Blood pressure levels before dementia. Arch. Neurol. 2005, 62:112-116. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15642857.
167. Piccini C., et al. Natural history of Alzheimer's disease: prognostic value of plateaux. J. Neurol. Sci. 1995, 131:177-182. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7595644.
168. Porsteinsson A.P., et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res. 2008, 5(1):83-89. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18286 (accessed 01.26.15.).
169. Praticò D., et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 2002, 59(6):972-976. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12056933 (accessed 02.26.15.).
170. Praticò D., Sung S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J. Alzheimer's Dis.: JAD 2004, 6(2):171-175. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15096701 (accessed 02.26.15.).
171. Prokop S., Miller K.R., Heppner F.L. Microglia actions in Alzheimer's disease. Acta Neuropathol. 2013, Available at: http://www.ncbi.nlm.nih.gov/pubmed/24077733.
172. Van Puyvelde K., et al. Effect of advanced glycation end product intake on inflammation and aging: a systematic review. Nutr. Rev. 2014, 72(10):638-650. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25231200 (accessed 06.10.15.).
173. Qiu C., et al. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch. Neurol. 2003, 60(2):223-228. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12580707 (accessed 02.25.15.).
174. Qiu C., Winblad B., Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005, 4:487-499. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16033691.
175. Quinn J.F., et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease:a randomized trial. JAMA 2010, 304(17):1903-1911. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3259852&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
176. Rapp M.A., et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch. Gen. Psychiatry 2006, 63(2):161-167. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16461859 (accessed 02.26.15.).
177. Rasmusson D.X., et al. Predicting rate of cognitive decline in probable Alzheimer's disease. Brain Cogn. 1996, 31:133-147. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8811989.
178. Reichenberg A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58:445-452. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11343523.
179. Remarque E.J., et al. Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp. Gerontol. 2001, 36:171-176. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11162920.
180. Remington R., et al. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am. J. Alzheimer's Dis. Other Dementias 2009, 24(1):27-33. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19056706 (accessed 02.26.15.).
181. Richardson C., et al. Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors. Int. J. Geriatr. Psychiatry 2013, 28:1312-1317. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23585364.
182. Ringman J.M., et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer's Res. Ther. 2012, 4(5):43. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3580400&tool=pmcentrez&rendertype=abstract (accessed 04.07.15.).
183. Rive B., et al. Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease. CNS Drugs 2013, 27(7):573-582. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3709077&tool=pmcentrez&rendertype=abstract (accessed 02.23.15.).
184. Rockwood K., Lindsay J., McDowell I. High blood pressure and dementia. Lancet 1996, 348:65-66. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8691960.
185. Rogers S.L. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Dementia Geriatric Cogn. Disord. 1998, 9(Suppl 3):29-42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9853200 (accessed 02.25.15.).
186. Rogers S.L., Friedhoff L.T. The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a Us Multicentre, Randomized, Double-blind, Placebo-controlled Trial 2015, 293-303. The Donepezil Study Group, Dementia (Basel, Switzerland), Available at: http://www.ncbi.nlm.nih.gov/pubmed/8915035 (accessed 02.25.15.).
187. Rolland Y., et al. Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. J. Am. Geriatr. Soc. 2007, 55(2):158-165. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17302 (accessed 01.27.15.).
188. Rönnemaa E., et al. Serum fatty-acid composition and the risk of Alzheimer's disease: a longitudinal population-based study. Eur. J. Clin. Nutr. 2012, 66(8):885-890. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22713770 (accessed 02.26.15.).
189. Rosenberg P.B., et al. Sertraline for the treatment of depression in Alzheimer disease. Am. J. Geriatric Psychiatry: Off. J. Am. Assoc. Geriatric Psychiatry 2010, 18(2):136-145. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2842121&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
190. Rothman S.M., Mattson M.P. Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromol. Med. 2010, 12(1):56-70. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2833224&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
191. Rusted J.M., et al. APOE e4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures. Neuroimage 2013, 65:364-373. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23063453.
192. Ruthirakuhan M., et al. Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review. J. Aging Res. 2012, 384875. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3549347&tool=pmcentrez&rendertype=abstract (accessed 02.20.15.).
193. Sabbagh M., et al. Evaluating the cognitive effects of donepezil 23mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics 2013, 13:56. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3681558&tool=pmcentrez&rendertype=abstract(accessed 02.25.15.).
194. Salloway S., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370(4):322-333. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4159618&tool=pmcentrez&rendertype=abstract (accessed 02..09.15.).
195. Salmon D.P., et al. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990, 40(8):1225-1230. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2381530 (accessed 04 .07.15.).
196. Sandman P.O., et al. Nutritional status and dietary intake in institutionalized patients with Alzheimer's disease and multiinfarct dementia. J. Am. Geriatrics Soc. 1987, 35(1):31-38. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3098821 (accessed 02.26.15.).
197. Santana-Sosa E., et al. Exercise training is beneficial for Alzheimer's patients. Int. J. Sports Med. 2008, 29(10):845-850. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18401810 (accessed 01.27.15.).
198. Sastre M., Gentleman S.M. NSAIDs: how they work and their prospects as therapeutics in Alzheimer's Disease. Front. Aging Neurosci. 2010, 2:20. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20589102.
199. Sato Y., et al. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: a randomized controlled trial. J. Bone Miner. Res. 2005, 20(8):1327-1333. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16007329 (accessed 05.0.15.).
200. Sato Y., Asoh T., Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone 1998, 23(6):555-557. Available at: http://www.sciencedirect.com/science/article/pii/S8756328298001343 (Accessed 05.10.15.).
201. Scarmeas N., et al. Mediterranean diet and Alzheimer disease mortality. Neurology 2007, 69(11):1084-1093. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2673956&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
202. Scarmeas N., et al. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol. 2006, 63(12):1709-1717. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3024906&tool=pmcentrez&rendertype=abstract (accessed 02.6 .15.).
203. Scheltens P., et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimer's & dementia. J. Alzheimer's Assoc. 2010, 6(1):1-10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20129316 (accessed 01.03.15.).
204. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740):173-177. Available at: http://dx.doi.org/10.1038/22124 (accessed 05.20.15.).
205. Schmeidler J., Mohs R.C., Aryan M. Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1998, 12:146-151. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9772016.
206. Schneider L.S., et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J. Intern. Med. 2014, 275:251-283. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24605808.
207. Schoon Y., et al. Hypotensive syndromes are not associated with cognitive impairment in geriatric patients. Am. J. Alzheimer's Dis. Other Dementias 2013, 28(1):47-53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23242123 (accessed 02.23.15.).
208. Seibert J., et al. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice. Neuropsychiatr. Dis. Treatment 2012, 8:141-147. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3333784&tool=pmcentrez&rendertype=abstract (accessed 02.25.15.).
209. Seifert T., et al. Endurance training enhances BDNF release from the human brain. Am. J. Physio. Regul. Integrative Comp. Physiol. 2009, 298(2):R372-R377. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19923361 (accessed 02.26.15.).
210. Semba R.D., et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Internal Med. 2014, 174(7):1077-1084. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24819981 (accessed 02.20.15.).
211. Sepehry A.A., et al. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging 2012, 29(10):793-806. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23079957 (accessed 02.26.15.).
212. Shah N.S., et al. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension 2012, 59:780-786. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22392902.
213. Shah R.C., et al. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimer's research & therapy 2013, 5(6):59. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3978853&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
214. Shen Y., Meri S. Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog. Neurobiol. 2003, 70:463-472. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14568360.
215. Small G.W., et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int. J. Clin. Pract. 2005, 59(4):473-477. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15853867 (accessed 02.25.15.).
216. Sofi F., et al. Effectiveness of the Mediterranean diet: can it help delay or prevent Alzheimer's disease?. J. Alzheimer's Dis.: JAD 2010, 20(3):795-801. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20182044 (accessed 02.26.15.).
217. Sonnesyn H., et al. High prevalence of orthostatic hypotension in mild dementia. Dement. Geriatr. Cogn. Disord. 2009, 28(4):307-313. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19828952 (accessed 02.23.15.).
218. Spaccavento S., et al. Influence of nutritional status on cognitive, functional and neuropsychiatric deficits in Alzheimer's disease. Arch. Gerontol. Geriatr. 2009, 48(3):356-360. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18448178 (accessed 02.26.15.).
219. Spalletta G., et al. The role of persistent and incident major depression on rate of cognitive deterioration in newly diagnosed Alzheimer's disease patients. Psychiatry Res. 2012, 198(2):263-268. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22406390 (accessed 02.26.15.).
220. Steffens D.C., et al. Hippocampal volume and incident dementia in geriatric depression. Am. J. Geriatr. Psychiatry 2002, 10(1):62-71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11790636 (accessed 02.26.15).
221. Stein M.S., et al. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. J. Alzheimer's Dis.: JAD 2011, 26(3):477-484. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21694461 (accessed 05.02.15.).
222. Stern R.G., et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am. J. Psychiatry 1994, 151(3):390-396. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8109647 (accessed 05.22.15.).
223. Stern Y. Cognitive reserve. Neuropsychologia 2009, 47:2015-2028. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19467352.
224. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012, 11(11):1006-1012. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3507991&tool=pmcentrez&rendertype=abstract (accessed 07.16.14.).
225. Stern Y., et al. Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann. Neurol. 1995, 37:590-595. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7755353.
226. Stern Y., et al. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann. Neurol. 1992, 32:371-375. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1416806.
227. Stern Y., Jacobs D.M. Preliminary findings from the predictors study: utility of clinical signs for predicting disease course. Alzheimer Dis. Assoc. Disord. 1995, 9. Available at http://www.ncbi.nlm.nih.gov/pubmed/7546594.
228. Stone J., et al. Consistency of BACE inhibitor-mediated brain amyloid production inhibition by MK-8931 in Alzheimer's disease patients and healthy young adults. Alzheimer's Dementia 2013, 9(4):P690-P691. Available at: http://www.alzheimersanddementia.com/article/S155252601300513X/fulltext (accessed 06.19.15.).
229. Sultana R., Perluigi M., Allan Butterfield D. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic. Biol. Med. 2013, 62:157-169. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3573239&tool=pmcentrez&rendertype=abstract (accessed 02. 26.15.).
230. Sun Q., et al. 25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis. Stroke 2012, 43(6). Available at: http://www.scopus.com/inward/record.url?eid=2-s2.0-84861581950&partnerID=tZOtx3y1 (accessed 05.08.15).
231. Sun X., et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl. Acad. Sci. U. S. A 2006, 103:p2. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17121991.
232. Sun Y., et al. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin. Ther. 2007, 29(10):2204-2214. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18042476 (accessed 02.26.15.).
233. Suter, O-C, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 2002, 33(8):1986-1992. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12154250 (accessed 02.25.15.).
234. Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!. Age Ageing 2006, 35:336-338. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16788077.
235. Taghizadeh M., et al. Vitamin D supplementation restores suppressed synaptic plasticity in Alzheimer's disease. Nutri. Neurosci. 2014, 17(4):172-177. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23883541 (accessed 05. 20.15).
236. Takashima A. Tauopathies and tau oligomers. J. Alzheimer's Dis.: JAD 2013, 37(3):565-568. Available at: http://www.ncbi.nlm.nih.gov/pubmed/239495 (accessed 02.02.15).
237. Tappen R.M., et al. Effect of a combined walking and conversation intervention on functional mobility of nursing home residents with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2000, 14(4):196-201. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1950269&tool=pmcentrez&rendertype=abstract (accessed 02.26.15).
238. Tariot P.N., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004, 291(3):317-324. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14734594 (accessed 01.27.15.).
239. Tateno A., et al. Amyloid imaging with [(18) F]florbetapir in geriatric depression: early-onset versus late-onset. Int. J. Geriatric Psychiatry 2014, Available at: http://www.ncbi.nlm.nih.gov/pubmed/25335941 (accessed 02.26.15.).
240. Teri L., et al. Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. J. Gerontol. A Biol. Sci. Med. Sci. 1995, 50A:M49-M55. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7814789.
241. Thal L.J., Grundman M., Klauber M.R. Dementia: characteristics of a referral population and factors associated with progression. Neurology 1988, 38:1083-1090. Available at http://www.ncbi.nlm.nih.gov/pubmed/3386827.
242. Thompson Coon J., et al. Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review. J. Am. Med. Dir. Assoc. 2014, 15(10):706-718. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25112229 (accessed 02.26.15.).
243. Tomé-Carneiro J., et al. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 19(34):6064-6093. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3782695&tool=pmcentrez&rendertype=abstract (accessed 02.19.15.).
244. Tosto G., Reitz C. Genome-wide association studies in Alzheimer's disease: a review. Curr. Neurol. Neurosci. Rep. 2013, 13:381. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23954969.
245. Uribarri J., et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet. Assoc. 2010, 110(6):911-916.e12. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3704564&tool=pmcentrez&rendertype=abstract (accessed 03.09.15.).
246. Uribarri J., et al. Suppression of native defense mechanisms, SIRT1 and PPAR(, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases. Amino Acids 2013, 46(2):301-309. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=373&tool=pmcentrez&rendertype=abstrac (accessed 05.10.15.).
247. Vanderheyden P.M. From angiotensin IV binding site to AT4 receptor. Mol. Cell Endocrinol. 2009, 302:159-166. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19071192.
248. Venturelli M., Scarsini R., Schena F. Six-month walking program changes cognitive and ADL performance in patients with Alzheimer. American journal of Alzheimer's disease and other dementias 2011, 26(5). Available at: http://www.ncbi.nlm.nih.gov/pubmed/2122 (accessed 02.19.15.).
249. Vilalta-Franch J., et al. Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality. Am. J. Geriatr. Psychiatry 2013, 21(11):1135-1143. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23567368 (accessed 02. 26.15).
250. De Waal H., et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. PLoS One 2014, 6558. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3903587&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
251. Wacker M., Holick M.F. Sunlight and Vitamin D. Dermato-Endocrinol. 2013, 5(1):51-108. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3897598&tool=pmcentrez&rendertype=abstract (accessed 02.16.15.).
252. Walsh J.S., Welch H.G., Larson E.B. Survival of outpatients with Alzheimer-type dementia. Ann. Intern. Med. 1990, 113:429-434. Available at http://www.ncbi.nlm.nih.gov/pubmed/2386336.
253. Wang J., et al. Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. Fron.t Aging Neurosci. 2014, 6:42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24672477.
254. Weamer E.A., et al. The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. Int. Psychogeriatrics 2009, 21(1):78-85. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2678562&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
255. Webster S., Bonnell B., Rogers J. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am. J. Pathol. 1997, 150:1531-1536. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9137079.
256. West R.K., et al. Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech. Ageing Dev. 2014, 140:10-12. Available at: http://www.ncbi.nlm.nih.gov/pubmed/0370 (accessed 05.10.15.).
257. Westlye E.T., et al. Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE ε4 carriers: relationships with memory performance. J. Neurosci. 2011, 31:7775-7783. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21613490.
258. Whitmer R.A., et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr. Alzheimer Res. 2007, 4(2):103-109. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17430231 (accessed 02.26.15.).
259. Wilkinson D., Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 2001, 16(9):852-857. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1153 (accessed 02.25.15.).
260. Winblad, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 2007, 22(5):456-467. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17380489 (accessed 02.25.15.).
261. Wisniewski T., Goñi F. Immunotherapeutic approaches for Alzheimer's disease. Neuron 2015, 85(6):1162-1176. Available at: http://www.sciencedirect.com/science/article/pii/S0896627314011738 (Accessed 03.20.15.).
262. Woods B., et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst. Rev. 1996, 2:CD005562. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22336813 (accessed 01.7.15.).
263. Yan R., Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. The lancet. Neurology 2014, 13(3):319-329. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4086426&tool=pmcentrez&rendertype=abstract (accessed 06.19.15.).
264. Yang F.M., et al. Participation in activity and risk for incident delirium. J. Am. Geriatr. Soc. 2008, 56(8):1479-1484. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2575031&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).
265. Yasojima K., et al. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 1999, 154:927-936. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10079271.
266. Young J., et al. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst. Rev. 1996, Available at: http://www.ncbi.nlm.nih.gov/pubmed/25900537 (accessed 04.23.15.).
267. Young, et al. A randomized, crossover trial of high-carbohydrate foods in nursing home residents with Alzheimer's disease: associations among intervention response, body mass index, and behavioral and cognitive function. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 2005, 60(8):1039-1045. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16127110 (accessed 02.26.15).
268. Yuki A., et al. Relationship between physical activity and brain atrophy progression. Med. Sci. Sports Exerc. 2012, 44(12):2362-2368. Available at: http://www.ncbi.nlm.nih.gov/pubmed/227766 (accessed 02.26.15.).
269. Zahodne L.B., et al. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression. Am. J. Geriatric Psychiatry 2015, 23(2):130-140. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23871118 (accessed 02.01.15.).
270. Zhang H.Y., Tang X.C. Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells. Neurosci. Lett. 2000, 292:41-44. Available at http://www.ncbi.nlm.nih.gov/pubmed/10996445.
271. Zheng Z., et al. Correlation between behavioural and psychological symptoms of Alzheimer type dementia and plasma homocysteine concentration. BioMed. Res. Int. 2014, 383494. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4065769&tool=pmcentrez&rendertype=abstract (accessed 02.26.15.).